21:23 , Jul 3, 2019 |  BC Extra  |  Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
18:58 , Feb 22, 2019 |  BC Week In Review  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Feb....
22:49 , Feb 20, 2019 |  BC Extra  |  Clinical News

Pfizer reports increase in lung clots, death with high-dose Xeljanz in postmarket study

Pfizer Inc. (NYSE:PFE) disclosed an increase in pulmonary embolisms and deaths among rheumatoid arthritis patients receiving the twice-daily 10 mg dose of Xeljanz tofacitinib in the A3921133 postmarketing CV safety trial. The pharma said Tuesday...
21:45 , Oct 1, 2018 |  BC Extra  |  Company News

Pfizer COO Bourla to succeed Read as CEO

Pfizer Inc. (NYSE:PFE) named an insider, COO Albert Bourla, to succeed Ian Read as CEO on Jan. 1. During Read’s eight-year tenure, he reshaped Pfizer into a slimmer, three-part organization and helped it navigate key...
17:42 , Aug 3, 2018 |  BC Week In Review  |  Company News

Pfizer's Read expecting rebate elimination

Chairman and CEO of Pfizer Inc. (NYSE:PFE) Ian Read expects President Donald Trump and the administration to eliminate rebates, the exec said on Pfizer's 2Q18 earnings call. Read said the current rebate structure is not...
22:59 , Jul 31, 2018 |  BC Extra  |  Company News

Pfizer's Read expecting rebate elimination

Chairman and CEO of Pfizer Inc. (NYSE:PFE) Ian Read expects President Donald Trump and the administration to eliminate rebates, the exec said Tuesday on Pfizer's 2Q18 earnings call. Read said the current rebate structure is...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with...
02:23 , Jun 30, 2018 |  BioCentury  |  Product Development

Defining access potential - before it’s too late

We see it everywhere: confirmation bias. Innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. But confirmation bias is particularly problematic thanks...
19:25 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Pfizer's Xeljanz gets label extension to include UC

FDA approved an sNDA for Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The agency said Xeljanz is the first oral drug approved for chronic use in...
18:59 , May 30, 2018 |  BC Extra  |  Company News

Pfizer's Xeljanz gets label extension to include UC

FDA approved an sNDA for Xeljanz tofacitinib from Pfizer Inc. (NYSE:PFE) to treat adults with moderately to severely active ulcerative colitis. The agency said Xeljanz is the first oral drug approved for chronic use in...